In vitro transport and delivery of antisense oligonucleotides.
A variety of techniques are currently available to enhance the cellular uptake and pharmacological effectiveness of antisense oligonucleotides in the in vitro setting. The choice of technique will depend on the context of investigation, the likelihood of cytotoxity due to the delivery agents, and the ease and convenience of the approach. The considerations for the delivery of antisense molecules in the in vivo setting are likely to be quite different from the cell culture situation emphasized in this article.
Hughes
J
J
Department of Pharmaceutics, University of Florida, Gainesville 32610, USA.
Astriab
A
A
Yoo
H
H
Alahari
S
S
Liang
E
E
Sergueev
D
D
Shaw
B R
BR
Juliano
R L
RL
D000595:Amino Acid Sequence; D001483:Base Sequence; D001692:Biological Transport; D002470:Cell Survival; D004337:Drug Carriers; D005434:Flow Cytometry / Q000379:methods; D015696:Gene Products, tat / Q000737:chemistry / Q000235:genetics; D015756:Genes, tat; D005914:Globins / Q000235:genetics; D015497:HIV-1 / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D007438:Introns; D008081:Liposomes; D008156:Luciferases / Q000235:genetics; D020319:Oligodeoxyribonucleotides, Antisense / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D013873:Thionucleotides; D014162:Transfection; D054322:tat Gene Products, Human Immunodeficiency Virus
D004337:Drug Carriers; D015696:Gene Products, tat; D008081:Liposomes; D020319:Oligodeoxyribonucleotides, Antisense; D011993:Recombinant Fusion Proteins; D013873:Thionucleotides; D054322:tat Gene Products, Human Immunodeficiency Virus; D005914:Globins; D008156:Luciferases